BiotechTube

800 mg ibuprofen/26.6 mg famotidine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Juvenile Idiopathic Arthritis

Conditions

Juvenile Idiopathic Arthritis

Trial Timeline

Apr 1, 2012 → Mar 1, 2015

NCT ID
NCT01563185

About 800 mg ibuprofen/26.6 mg famotidine

800 mg ibuprofen/26.6 mg famotidine is a approved stage product being developed by Amgen for Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01563185. Target conditions include Juvenile Idiopathic Arthritis.

What happened to similar drugs?

0 of 20 similar drugs in Juvenile Idiopathic Arthritis were approved

Approved (0) Terminated (2) Active (18)
🔄PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄AdalimumabEisaiPhase 3
🔄AbataceptOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01563185ApprovedCompleted

Competing Products

20 competing products in Juvenile Idiopathic Arthritis

See all competitors
ProductCompanyStageHype Score
PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
37
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
AdalimumabEisaiPhase 3
40
AbataceptOno PharmaceuticalPhase 3
40
Ixekizumab + AdalimumabEli LillyPhase 3
44
Baricitinib + PlaceboEli LillyPhase 3
40
BaricitinibEli LillyPhase 3
47
Baricitinib + TocilizumabEli LillyPhase 3
47
adalimumab + MethotrexateAbbViePre-clinical
26
UpadacitinibAbbViePhase 1
33
Upadacitinib + TocilizumabAbbViePhase 3
47
Adalimumab + RisankizumabAbbViePhase 3
47
AdalimumabAbbViePhase 3
40
naproxen + esomeprazoleAstraZenecaPhase 1
29
Alendronate (Fosamax)MerckPre-clinical
26
canakinumabNovartisPhase 3
40
SecukinumabNovartisPhase 1
36